Bayer: FDA grants priority review to prostate cancer drug
(CercleFinance.com) - Bayer said its prostate cancer drug darolutamide has been granted priority review status by the US FDA, accelerating the drug's regulatory process.
The Food and Drug Administration has accepted the new drug application and granted priority review to darolutamide for the treatment of non-metastatic castration-resistant prostate cancer, the German company said.
Bayer also said on Monday that a study has reaffirmed the safety and efficacy profile of its anticoagulant Xarelto for the prevention of strokes in patients with atrial fibrillation.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The Food and Drug Administration has accepted the new drug application and granted priority review to darolutamide for the treatment of non-metastatic castration-resistant prostate cancer, the German company said.
Bayer also said on Monday that a study has reaffirmed the safety and efficacy profile of its anticoagulant Xarelto for the prevention of strokes in patients with atrial fibrillation.
Copyright (c) 2019 CercleFinance.com. All rights reserved.